NTLA analyst estimates

Intellia (NTLA) analyst ratings, the average price target and its range, and every firm's latest call.

NTLA analyst ratings and price targets

DateFirmCallTarget
Oct 6, 2026BarclaysIntellia Therapeutics initiated with an Underweight at Barclays$8.00
Sep 9, 2026WedbushIntellia Therapeutics price target raised to $13 from $12 at Wedbush$13.00
Aug 7, 2026Evercore ISIIntellia Therapeutics upgraded to Outperform from In Line at Evercore ISI$24.00
Jul 15, 2026Wolfe ResearchIntellia Therapeutics downgraded to Underperform from Peer Perform at Wolfe Research$9.00
Jul 10, 2026WedbushIntellia Therapeutics price target raised to $17 from $12 at Wedbush$17.00
Jun 15, 2026New StreetH.C. Wainwright Reiterates Buy Rating on Intellia Therapeutics (NTLA)$25.00
May 13, 2026BernsteinIntellia Therapeutics price target raised to $17 from $13 at Bernstein$17.00
May 12, 2026Canaccord GenuityIntellia Therapeutics price target lowered to $49 from $58 at Canaccord$49.00
Apr 27, 2026Robert W. BairdIntellia Therapeutics price target raised to $13 from $7 at Baird$13.00
Apr 27, 2026Morgan StanleyIntellia Therapeutics price target raised to $15 from $11 at Morgan Stanley$15.00
Apr 27, 2026Leerink PartnersIntellia Therapeutics price target raised to $35 from $29 at Leerink$35.00
Apr 27, 2026Chardan CapitalIntellia Therapeutics price target raised to $30 from $27 at Chardan$30.00
Jan 28, 2026KeyBancIntellia Therapeutics (NTLA) PT Raised to $25 at H.C. Wainwright$25.00
Jan 27, 2026Robert W. BairdIntellia Therapeutics (NTLA) PT Raised to $7 at Baird$7.00
Nov 11, 2025Evercore ISIIntellia Therapeutics downgraded to In Line from Outperform at Evercore ISI$8.00

Updated 2026-11-03 00:01 UTC